Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Studio di follow-up sul neurosviluppo Oxy-PICU (Oxy-PICU ND)

Background to the research: Each year around 20,000 children are admitted to paediatric intensive care units (PICUs) in the UK. Of these children, ~75% will receive support from a breathing machine (or ventilator) in combination with additional oxygen. The investigators recently completed the NIHR funded Oxy-PICU randomised clinical trial (RCT) - a study that compares one treatment against another to determine which is best. The Oxy-PICU RCT investigated whether children in PICU who are receiving help from a ventilator with additional oxygen, should have their oxygen levels kept at a lower level or higher level which currently used in the NHS. The investigators found that aiming for lower oxygen levels was better and resulted in a small but significant reduction in the number of days children spent on machines or died at 30 days.

While small, this result would have a large and important impact for patients and their families and may have important cost savings for the NHS. However, while in the short-term targeting lower oxygen levels appears better, the effects on children's longer-term development are unknown. Knowing this is important to fully inform doctors and nurses about the effects of aiming for lower oxygen levels, and help the results of Oxy-PICU be applied throughout the NHS.

Aim of the research: This research aims to complete longer-term follow-up of children included in the Oxy-PICU RCT. The study will look at the effect of aiming for lower oxygen levels compared to higher oxygen levels on longer-term developmental milestones.

Research plan: 1,112 parents of children included in the Oxy-PICU RCT will be invited by email and post to take part. A telephone interview will be arranged with the parent(s) who agree to participate. A trained researcher will use standard questionnaires to measure important issues. They'll establish if the children are meeting their developmental milestones and learn about their health related quality of life. After the interview a report will be sent to the parents detailing their child's development. It is anticipated that 50% of those approached will agree to take part in this study. This will allow important differences in developmental milestones to be detected in children treated with lower oxygen levels.

Patient and public involvement: PPI has been essential throughout Oxy-PICU. Our PPI co-applicant has been involved in Oxy-PICU from the start as a key member of the study team and will continue to help oversee all aspects of this research. A parent advisory group will be appointed to provide additional PPI input into the study processes.

Knowledge mobilisation: Outputs from the neurodevelopmental follow-up will be specifically targeted to the key stakeholders including patients/parents, clinicians and policy makers. Outputs for patients/parents and the public will be co-produced with our PPI representatives.

Panoramica dello studio

Stato

Iscrizione su invito

Condizioni

Intervento / Trattamento

Descrizione dettagliata

Research question: In invasively ventilated critically ill children referred as an emergency for paediatric intensive care receiving supplementary oxygen [Population] what are the effects of a conservative oxygen therapy [Intervention] compared with a liberal oxygen therapy [Comparator] on longer-term neurodevelopmental function [Outcome]?

Background: The investigators recently completed the NIHR funded Oxy-PICU randomised clinical trial (RCT) which compared conservative versus liberal oxygenation targets in emergency admissions to PICU receiving invasive mechanical ventilation. The results showed a small but significant reduction in the number of days spent receiving organ support or death by day 30 with conservative oxygenation. While the effect size, in terms of the primary outcome, may appear small, if true, these results are clinically important to patients/parents and the NHS. While conservative oxygenation appears effective in the short term, questions still remain about the effects of targeting lower oxygen saturations on longer-term neurodevelopmental function, with calls made from PICU clinicians for this to be investigated prior to wider spread adoption of the Oxy-PICU trial results.

Aim: to extend and undertake additional follow-up of children enrolled in the Oxy-PICU RCT, to determine the effects of conservative oxygen therapy on longer-term neurodevelopmental function in critically ill children.

Methods: 1,112 parents of children included in the Oxy-PICU RCT will be invited by email and post to take part in this longer-term follow-up study. After agreeing to participate, a telephone interview will be arranged with the parent(s) consisting of two validated questionnaires: 1. Vineland Behaviour Scales, third edition (VABS-3) and 2. PedsQL™ 4.0 (Pediatric Quality of Life Inventory) which provide a validated proxy for neurodevelopmental functioning and quality of life, respectively. Once the interview has been completed, a report will be provided to the parents detailing their child's development.

Primary outcome: neurodevelopmental function defined as the overall adaptive behaviour VABS-3 score.

Sample size: Anticipating 50% of those approached agreeing to take part in this study, 556 parents completing telephone interviews will provide enough people to detect a clinically important difference in neurological and developmental function in children treated with conservative oxygen saturations compared with higher oxygen saturations.

Timeline: Total duration: 24 months: months 1-3: HRA approval and interview training; months 4-21: patient/parent recruitment and telephone interviews; months 22-24: analysis and dissemination.

Impact and dissemination: This research will have a large and immediate impact on patients, parents/guardians and the NHS. Understanding the neurodevelopmental effects of conservative oxygen therapy is imperative for implementation of the Oxy-PICU results, which has the potential for important clinical benefit for critically ill children and the NHS. The results will be actively disseminated with specific outputs targeted at patients and the public, PICU clinicians/researchers and policy makers. Outputs targeting patients and public will be co-designed with PPI representatives.

Tipo di studio

Osservativo

Iscrizione (Stimato)

556

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • London, Regno Unito, WC1V 6AZ
        • Intensive Care National Audit and Research Centre

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Bambino
  • Adulto
  • Adulto più anziano

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Metodo di campionamento

Campione non probabilistico

Popolazione di studio

Parents/caregivers of children enrolled into Oxy-PICU and who provided consent to be contacted about future related research.

Descrizione

Inclusion Criteria:

  1. Parent or caregiver of child included in the Oxy-PICU RCT;
  2. Provided consent to be contacted about future research;
  3. Living with child; and
  4. Child/young person survival status confirmed.

Exclusion Criteria:

None.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Modelli osservazionali: FAMILY_BASED
  • Prospettive temporali: PROSPECTIVE

Coorti e interventi

Gruppo / Coorte
Intervento / Trattamento
Conservative oxygenation

Patients that have previously received treatment in paediatric intensive care with conservative oxygenation

Liberal oxygenation

Patients that have previously received treatment in paediatric intensive care with liberal oxygenation

Patients that were previously randomised to receive conservative oxygenation while in paediatric intensive care

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Neurodevelopmental function defined as the overall adaptive behaviour score assessed using the Vineland Adaptive Behaviour Scales, third edition (VABS-3).
Lasso di tempo: 4 years post randomization into the Oxy-PICU RCT (ISRCTN92103439)

Overall adaptive behaviour score obtained from the Vineland Adaptive Behaviour Scales, third edition (VABS-3) questionnaire.

4 years post randomization into the Oxy-PICU RCT (ISRCTN92103439)

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
VABS-3 domain scores
Lasso di tempo: 4 years post randomization into the Oxy-PICU RCT (ISRCTN92103439)

Individual VABS-3 domain scores (communication, daily living skills, socialisation, motor skills in younger children)

4 years post randomization into the Oxy-PICU RCT (ISRCTN92103439)
Health related quality of life
Lasso di tempo: 4 years post randomization into the Oxy-PICU RCT (ISRCTN92103439)

Health related quality of life (HRQoL) measured using the Pediatric Quality of Life Inventory (PedsQL™) 4.0.

4 years post randomization into the Oxy-PICU RCT (ISRCTN92103439)

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Collaboratori

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

23 giugno 2025

Completamento primario (Stimato)

1 marzo 2027

Completamento dello studio (Stimato)

1 settembre 2027

Date di iscrizione allo studio

Primo inviato

11 dicembre 2024

Primo inviato che soddisfa i criteri di controllo qualità

11 dicembre 2024

Primo Inserito (Effettivo)

16 dicembre 2024

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

9 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

4 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • Oxy-PICU ND v1.0
  • NIHR206910 (Altro numero di sovvenzione/finanziamento: National Institute for Health and Care Research (NIHR) Research for Patient Benefit (RfPB))

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

INDECISO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .